Abstract: The independent claims of this patent signify a concise description of embodiments. An emulation control block enables a user to view an entire design in the same phase so that the used can observe and control a halted design in the same logical reference cycle. Both the clock cone and design flops are provided in the state which occurs after the evaluation of cycle K of the reference time. During cycle K+1 of an emulation, the values of derived clocks for cycle K+1 are computed. Moreover, during cycle K+1 of the emulation, the values of the sequential elements are computed based cycle K values of the clocks. When the emulation is halted due to a break, the clock cone is reverted to its previous state. This Abstract is not intended to limit the scope of the claims.

Abstract: The independent claims of this patent signify a concise description of embodiments. An emulation control block enables a user to view an entire design in the same phase so that the used can observe and control a halted design in the same logical reference cycle. Both the clock cone and design flops are provided in the state which occurs after the evaluation of cycle K of the reference time. During cycle K+1 of an emulation, the values of derived clocks for cycle K+1 are computed. Moreover, during cycle K+1 of the emulation, the values of the sequential elements are computed based cycle K values of the clocks. When the emulation is halted due to a break, the clock cone is reverted to its previous state. This Abstract is not intended to limit the scope of the claims.

Abstract: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce ? cell regeneration.

Abstract: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce ? cell regeneration.

Abstract: A cache memory architecture, a method of operating a cache memory and a memory controller. In one embodiment, the cache memory architecture includes: (1) a segment memory configured to contain at least one most significant bit (MSB) of a main memory address, the at least one MSB being common to addresses in a particular main memory logical segment that includes the main memory address, (2) a tag memory configured to contain tags that include other bits of the main memory address and (3) combinatorial logic associated with the segment memory and the tag memory and configured to indicate a cache hit only when both the at least one most significant bit and the other bits match a requested main memory address.

Abstract: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration.

Abstract: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration.

Abstract: A cache memory architecture, a method of operating a cache memory and a memory controller. In one embodiment, the cache memory architecture includes: (1) a segment memory configured to contain at least one most significant bit (MSB) of a main memory address, the at least one MSB being common to addresses in a particular main memory logical segment that includes the main memory address, (2) a tag memory configured to contain tags that include other bits of the main memory address and (3) combinatorial logic associated with the segment memory and the tag memory and configured to indicate a cache hit only when both the at least one most significant bit and the other bits match a requested main memory address.

Abstract: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration.

Abstract: Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet ?-cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells.

Abstract: Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet &bgr;-cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells.